Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541.
Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541.
复制标题
DOI：
10.1002/cncr.24140
复制
发表时间：
2009-03-01
期刊：
影响因子：
6.2
通讯作者：
Bittoni, Marisa
中科院分区：
文献类型：
--
作者：
Paskett, Electra;Herndon, James, II;Donohue, Kathleen;Naughton, Michelle;Grubbs, Stephen;Pavy, Michael;Hensley, Martee;Stark, Nancy;Kornblith, Alice;Bittoni, Marisa
幸存者健康和反应(SHARE)研究调查了1985-1991年参加CALGB 8541的乳腺癌患者的健康相关生活质量(HRQL)。共有245名幸存者(占符合条件的患者的78%)在确诊后9.4-16.5年(平均12.5年)完成了与5个领域有关的HRQL调查。分析了最初治疗试验中给予的三个化疗剂量的HRQL域：low-dose=Cyclophosphamide/Doxorubicin/Flouracil(CAF)在4个周期中以300/30/300×2 mg/m2剂量注射，标准剂量=CAF在4个周期中以400/40/400×2 mg/m2剂量治疗，高剂量=CAF在4个周期中以600/60/600 mg/m2剂量治疗。在单变量分析中，治疗组在SF-36身体角色功能方面的差异有统计学意义，标准治疗组的平均得分(平均值=65.05)低于低剂量组(平均值=74.66)或高剂量组(平均值=84.94)(p=0.0001)。然而，多因素分析显示，治疗组不再具有统计学意义，而以下因素与躯体角色功能下降有关：年龄≥60(OR=3.5 5，p=0.006)，共病干预总分增加(OR=1.6 4，p=0.005)，活力降低(OR=1.0 5，p=0.0002)，更年期症状增加(OR=1.0 4，p=0.0 2)。在确诊后9.4-16.5年，接受三次化疗的乳腺癌幸存者的身体角色功能差异可以用临床和人口统计学变量来解释，如年龄、疲劳、更年期症状和合并症。需要进行前瞻性研究，以进一步评估这些因素在解释长期存活者的HRQL和生理功能方面的作用。
The Survivor’s Health and Reaction (SHARE) study examined health-related quality of life (HRQL) in breast cancer patients who had participated in CALGB 8541 from 1985–1991. A total of 245 survivors (78% of eligible patients) who were 9.4–16.5 years post-diagnosis (mean 12.5 years) completed HRQL surveys relating to 5 domains. Analyses examined HRQL domains by the three chemotherapy doses administered in the original treatment trial: low-dose=Cyclophosphamide/Doxorubicin/Flouracil (CAF) at 300/30/300×2 mg/m2 over 4 cycles, standard-dose=CAF at 400/40/400×2 mg/m2over 4 cycles, and high-dose=CAF at 600/60/600 mg/m2over 4 cycles. In univariate analyses, a statistically significant difference was found in SF-36 physical role functioning by treatment group, with the standard treatment arm showing lower mean scores (mean=65.05) compared to the low-dose (mean=74.66) or high-dose (mean=84.94) arms (p=<0.0001). Multivariate analysis, however, revealed that treatment arm was no longer statistically significant, while the following factors were associated with decreased physical role functioning: age ≥60 (OR=3.55, p=0.006), increased comorbidity interference total score (OR=1.64, p=0.005), lower vitality (OR=1.05, p=0.0002) and increased menopausal symptoms (OR=1.04, p=0.02). At 9.4–16.5 years post-diagnosis, differences in physical role functioning among breast cancer survivors who received three chemotherapy doses were explained by clinical and demographic variables, such as age, fatigue, menopausal symptoms and comorbidities. Prospective studies are needed to further assess the role of these factors in explaining HRQL and physical role functioning among long-term survivors.
登录
查看更多内容
影响因子：
45.3
作者：
Dorval, M;Maunsell, E;Mâsse, B
通讯作者：
Mâsse, B
DOI：
10.1046/j.1524-4741.2000.20042.x
发表时间：
2000-10-01
期刊：
The breast journal
影响因子：
--
作者：
Ganz, Patricia A.
通讯作者：
Ganz, Patricia A.
DOI：
10.1093/geronj/46.4.m139
发表时间：
1991-07-01
期刊：
JOURNALS OF GERONTOLOGY
影响因子：
--
作者：
CROOKS, V;WALLER, S;HAHN, TJ
通讯作者：
HAHN, TJ
影响因子：
1.8
作者：
Ersek, M;Ferrell, BR;Melancon, CH
通讯作者：
Melancon, CH
DOI：
10.1111/j.1532-5415.1985.tb06317.x
发表时间：
1985-01-01
影响因子：
6.3
作者：
GEORGE, LK;FILLENBAUM, GG
通讯作者：
FILLENBAUM, GG